The pathogenesis of the bone disease of multiple myeloma

Bone

Volumn 42, Issue 6, 2008, Pages 1007-1013

  Edwards, Claire M ^a   Zhuang, Junling ^a   Mundy, Gregory R ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Dkk1; Multiple myeloma; Osteoblast; Osteoclast; RANKL

Indexed keywords

ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; BORTEZOMIB; CHEMOKINE RECEPTOR CXCR4; DENOSUMAB; DEXAMETHASONE; INTERLEUKIN 3; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; OSTEOCLAST DIFFERENTIATION FACTOR; PROTEASOME INHIBITOR; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SCATTER FACTOR; STROMAL CELL DERIVED FACTOR 1ALPHA; TRANSCRIPTION FACTOR RUNX2; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN; WNT PROTEIN;

BONE DISEASE; BONE MARROW; BONE NECROSIS; CELL INTERACTION; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE COURSE; HUMAN; INHIBITION KINETICS; MULTIPLE MYELOMA; MYELOMA CELL; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PATHOGENESIS; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

ANIMALS; BONE AND BONES; BONE MARROW CELLS; BONE RESORPTION; CHEMOKINES; CYTOKINES; HUMANS; MULTIPLE MYELOMA; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS;

EID: 43149089554     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2008.01.027     Document Type: Review

References (84)

1. Mundy G.R. Myeloma bone disease. Eur J Cancer 34 (1998) 246-251
2. Mundy G.R., Raisz L.G., Cooper R.A., Schechter G.P., and Salmon S. Evidence for the secretion of an osteoclast stimulating factor in myeloma. N Engl J Med 291 (1974) 1041-1046
3. Valentin O.A., Charhon S.A., Meunier P.J., Edouard C.M., and Arlot M.E. Quantitative histology of myeloma-induced bone changes. Br J Haematol 52 (1982) 601-610
4. Taube T., Beneton M.N.C., McCloskey E.V., Rogers S., Greaves M., and Kanis J.A. Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol 49 (1992) 192-198
5. Bataille R., Chappard D., Marcelli C., Dessauw P., Balset P., Sany J., et al. Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 88 (1991) 62-66
6. Evans C.E., Galasko C.S., and Ward C. Does myeloma secrete an osteoblast inhibiting factor?. J Bone Joint Surg Br 71 (1989) 288-290
7. Bataille R., Delmas P.D., Chappard D., and Sany J. Abnormal serum bone Gla protein levels in multiple myeloma. Crucial role of bone formation and prognostic implications. Cancer 66 (1990) 167-172
8. Abildgaard N., Rungby J., Glerup H., Brixen K., Kassem M., Brincker H., et al. Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma. Eur J Haematol 61 (1998) 128-134
9. Woitge H.W., Horn E., Keck A.V., Auler B., Seibel M.J., and Pecherstorfer M. Biochemical markers of bone formation in patients with plasma cell dyscrasias and benign osteoporosis. Clin Chem 47 (2001) 686-693
10. Garrett I.R., Durie B.G., Nedwin G.E., Gillespie A., Bringman T., Sabatini M., et al. Production of lymphotoxin, a bone-resorbing cytokine, by cultured human myeloma cells. N Engl J Med 317 (1987) 526-532
11. Kawano M., Hirano T., Matsuda T., Taga T., Horij Y., Iwato K., et al. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature 332 (1988) 83-85
12. Lee J.W., Chung H.Y., Ehrlich L.A., Jelinek D.F., Callander N.S., Roodman G.D., et al. IL-3 expression by myeloma cells increases both osteoclast formation and growth of myeloma cells. Blood 103 (2004) 2308-2315
13. Lichtenstein A., Berenson J., Norman D., Chang M.P., and Carlile A. Production of cytokines by bone marrow cells obtained from patients with multiple myeloma. Blood 74 (1989) 1266-1273
14. Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390 (1997) 175-179
15. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Butgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
16. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Lüthy R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
17. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397 (1999) 315-323
18. Li J., Sarosi I., Yan X.Q., Morony S., Capparelli C., Tan H.L., et al. RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci U S A 97 (2000) 1566-1571
19. Mizuno A., Amizuka N., Irie K., Murakami A., Fujise N., Kanno T., et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247 (1998) 610-615
20. Pearse R.N., Sordillo E.M., Yaccoby S., Wong B.R., Liau D.F., Colman N., et al. Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. PNAS 98 (2001) 11581-11586
21. Giuliani N., Bataille R., Mancini C., Lazzaretti M., and Barillé S. Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98 (2001) 3527-3533
22. Roux S., Amazit L., Meduri G., Guiochon-Mantel A., Milgrom E., and Mariette X. RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. Am J Clin Pathol 117 (2002) 210-216
23. Seidel C., Hjertner Ø., Abildgaard N., Heickendorff L., Hjorth M., Westin J., et al. Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 98 (2001) 2269-2271
24. Politou M., Terpos E., Anagnostopoulos A., Szydlo R., Laffan M., Layton M., et al. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol 126 (2004) 686-689
25. Terpos E., Szydlo R., Apperley J.F., Hatjiharissi E., Politou M., Meletis J., et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102 (2003) 1064-1069
26. Farrugia A.N., Atkins G.J., To L.B., Pan B., Horvath N., Kostakis P., et al. Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo. Cancer Res 63 (2003) 5438-5445
27. Shipman C.M., Holen I., Lippitt J.M., Vandeberghe E., and Croucher P.I. Tumour cells isolated from patients with multiple myeloma express the critical osteoclastogenic factor, RANKL. Blood 96 (2000) 360a
28. Shipman C.M., and Croucher P.I. Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 63 (2003) 912-916
29. Croucher P.I., Shipman C.M., Lippitt J., Perry M., Asosingh K., Hijzen A., et al. Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood 98 (2001) 3534-3540
30. Vanderkerken K., De Leenheer E., Shipman C., Asosingh K., Willems A., Van Camp B., et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res 63 (2003) 287-289
31. Oyajobi B.O., and Mundy G.R. Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma. Cancer 97 (2003) 813-817
32. Yaccoby S., Pearse R.N., Johnson R.N., Johnson C.L., Barologie B., Choi Y., et al. Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity. Br J Haematol 116 (2002) 278-290
33. Terpos E., Politou M., Szydlo R., Goldman J.M., Apperley J.F., and Rahemtulla A. Serum levels of macrophage inflammatory protein-1 alpha (MIP-1alpha) correlate with the extent of bone disease and survival in patients with multiple myeloma. Br J Haematol 123 (2003) 106-109
34. Choi S.J., Cruz J.C., Craig F., Chung H., Devlin R.D., Roodman G.D., et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 96 (2000) 671-675
35. Oba Y., Lee J.W., Ehrlich L.A., Chung H.Y., Jelinek D.F., Callander N.S., et al. MIP-1alpha utilizes both CCR1 and CCR5 to induce osteoclast formation and increase adhesion of myeloma cells to marrow stromal cells. Exp Hematol 33 (2005) 272-278
36. Oyajobi B.O., Franchin G., Williams P.J., Pulkrabek D., Gupta A., Munoz S., et al. Dual effects of macrophage inflammatory protein-1alpha on osteolysis and tumor burden in the murine 5TGM1 model of myeloma bone disease. Blood 102 (2003) 311-319
37. Choi S.J., Oba Y., Gazitt Y., Alsina M., Cruz J., Anderson J., et al. Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest 108 (2001) 1833-1841
38. Vacca A., Ribatti D., Roncali L., Ranieri G., Serio G., Silvestris F., et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 87 (1994) 503-508
39. Niida S., Kaku M., Amano H., Yoshida H., Kataoka H., Nishikawa S., et al. Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med 190 (1999) 293-298
40. Tanaka Y., Abe M., Hiasa M., Oda A., Amou H., Nakano A., et al. Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin Cancer Res 13 (2007) 816-823
41. Juarez J., and Bendall L. SDF-1 and CXCR4 in normal and malignant hematopoiesis. Histol Histopathol 19 (2004) 299-309
42. Yu X., Huang Y., Collin-Osdoby P., and Osdoby P. Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration. J Bone Miner Res 18 (2003) 1404-1418
43. Smith M.C., Luker K.E., Garbow J.R., Prior J.L., Jackson E., Piwnica-Worms D., et al. CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res 64 (2004) 8604-8612
44. Alsayed Y., Ngo H., Runnels J., Leleu X., Singha U.K., Pitsillides C.M., et al. Mechanisms of regulation of CXCR4/SDF-1 (CXCL12)-dependent migration and homing in multiple myeloma. Blood 109 (2007) 2708-2717
45. Zannettino A.C., Farrugia A.N., Kortesidis A., Manavis J., To L.B., Martin S.K., et al. Elevated serum levels of stromal-derived factor-1alpha are associated with increased osteoclast activity and osteolytic bone disease in multiple myeloma patients. Cancer Res 65 (2005) 1700-1709
46. Michigami T., Shimizu N., Williams P.J., Niewolna M., Dallas S.L., Mundy G.R., et al. Cell-cell contact between marrow stromal cells and myeloma cells via VCAM-1 and a4b1-integrin enhances production of osteoclast-stimulating activity. Blood 96 (2000) 1953-1960
47. Mori Y., Shimizu N., Dallas M., Niewolna M., Story B., Williams P.J., et al. Anti-alpha4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis. Blood 104 (2004) 2149-2154
48. Oyayobi B.O., Ytaianedes K., Yoneda T., and Mundy G.R. Expression of RANK ligand (RANKL) by myeloma cells requires binding to bone marrow stromal cells via an a4b1-VCAM-1 interaction. Bone 23 (1998) S180
49. Yaccoby S., Wezeman M.J., Henderson A., Cottler-Fox M., Yi Q., Barlogie B., et al. Cancer and the microenvironment: myeloma-osteoclast interactions as a model. Cancer Res 64 (2004) 2016-2023
50. Abe M., Hiura K., Wilde J., Shioyasono A., Moriyama K., Hashimoto T., et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 104 (2004) 2484-2491
51. Gong Y., Slee R.B., Fukai N., Rawadi G., Roman-Roman S., Reginato A.M., et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell 107 (2001) 513-523
52. Boyden L.M., Mao J., Belsky J., Mitzner L., Farhi A., Mitnick M.A., et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med 346 (2002) 1513-1521
53. Kato M., Patel M., Levasseur R., Lobov I., Chang B.H., Glass D.A., et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistant embryonic eye vascularization in mice deficient in LRP5, a Wnt coreceptor. J Cell Biol 157 (2002) 303-314
54. Clement-Lacroix P., Ai M., Morvan F., Roman-Roman S., Vayssiere B., Belleville C., et al. Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc Natl Acad Sci U S A 102 (2005) 17406-17411
55. Edwards C.M., Edwards J.R., Esparza J., Oyajobi B.O., McCluskey B., Munoz S., et al. Lithium inhibits the development of myeloma bone disease in vivo. J Bone Miner Res 21 (2006) S82 (abstract)
56. Tian E., Zhan F., Walker R., Rasmussen E., Ma Y., Barlogie B., et al. The role of the Wnt-signaling antagonist in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349 (2003) 2483-2494
57. Rawadi G., Vayssiere B., Dunn F., Baron R., and Roman-Roman S. BMP-2 controls alkaline phosphatase expression and osteoblast mineralization by a Wnt autocrine loop. J Bone Miner Res 18 (2003) 1842-1853
58. Li J., Sarosi I., Cattley R.C., Pretorius J., Asuncion F., Grisanti M., et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39 (2006) 754-766
59. Morvan F., Boulukos K., Clement-Lacroix P., Roman Roman S., Suc-Royer I., Vayssiere B., et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J Bone Miner Res 21 (2006) 934-945
60. Oyajobi B.O., Garrett I.R., Gupta A., Banerjee M., Esparza X., Flores A., et al. Role of Dickkopf 1(Dkk) in myeloma bone disease and modulation by the proteasome inhibitor velcade. J Bone Miner Res 19 (2004) 1011
61. Gunn W.G., Conley A., Deininger L., Olson S.D., Prockop D.J., and Gregory C.A. A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma. Stem Cells 24 (2006) 986-991
62. Yaccoby S., Ling W., Zhan F., Walker R., Barlogie B., and Shaughnessy Jr. J.D. Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 109 (2007) 2106-2111
63. Oshima T., Abe M., Asano J., Hara T., Kitazoe K., Sekimoto E., et al. Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood 106 (2005) 160-165
64. Takeuchi K., Abe M., Oda A., Amou H., Hiasa M., Asano J., et al. Enhancement of osteoblast differentiation by inhibition of TGF-beta signaling suppresses myeloma cell growth and protects from destructive bone lesions. J Bone Miner Res 21 (2006) 1101
65. Giuliani N., Colla S., Morandi F., Lazzaretti M., Sala R., Bonomini S., et al. Myeloma cells block RUNX2/CBFA1 activity in human bone marrow osteoblast progenitors and inhibit osteoblast formation and differentiation. Blood 106 (2005) 2472-2483
66. Ehrlich L.A., Chung H.Y., Ghobrial I., Choi S.J., Morandi F., Colla S., et al. IL-3 is a potential inhibitor of osteoblast differentiation in multiple myeloma. Blood 106 (2005) 1407-1414
67. Seidel C., Berset M., Turesson I., Abildgaard N., Sundan A., and Waage A. Elevated serum concentrations of hepatocyte growth factor in patients with multiple myeloma. Blood 91 (1998) 806-812
68. Andersen N.F., Standal T., Nielsen J.L., Heickendorff L., Borset M., Sorensen F.B., et al. Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol 128 (2005) 210-217
69. Standal T., Abildgaard N., Fagerli U.M., Stordal B., Hjertner O., Borset M., et al. HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood 109 (2007) 3024-3030
70. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., et al. Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 106 (2005) 2977-2981
71. Yang H.H., Vescio R., Schenkein D., and Berenson J.R. A prospective, open-label safety and efficacy study of combination treatment with bortezomib (PS-341, velcade and melphalan in patients with relapsed or refractory multiple myeloma. Clin Lymphoma 4 (2003) 119-122
72. Jagannath S., Barlogie B., Berenson J.R., Singhal S., Alexanian R., Srkalovic G., et al. Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer 103 (2005) 1195-1200
73. Jagannath S., Durie B.G., Wolf J., Camacho E., Irwin D., Lutzky J., et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 129 (2005) 776-783
74. Richardson P.G., Barlogie B., Berenson J., Singhal S., Jagannath S., Irwin D., et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348 (2003) 2609-2617
75. Garrett I.R., Chen D., Gutierrez G., Zhao M., Escobedo A., Rossini G., et al. Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro. J Clin Invest 111 (2003) 1771-1782
76. Zavrski I., Krebbel H., Wildemann B., Heider U., Kaiser M., Possinger K., et al. Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. Biochem Biophys Res Commun 333 (2005) 200-205
77. Pennisi A., Ling W., Perkins P., Saha R., Barlogie B., Tricot G., et al. PTH and bortezomib suppresses growth of primary human myeloma through increased bone formation in vivo. Blood 108 (2006) 154a
78. Zangari M., Esseltine D., Lee C.K., Barlogie B., Elice F., Burns M.J., et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 131 (2005) 71-73
79. Shimazaki C., Uchida R., Nakano S., Namura K., Fuchida S.I., Okano A., et al. High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation. Leukemia 19 (2005) 1102-1103
80. Zangari M., Yaccoby S., Cavallo F., Esseltine D., and Tricot G. Response to bortezomib and activation of osteoblasts in multiple myeloma. Clin Lymphoma Myeloma 7 (2006) 109-114
81. Giuliani N., Morandi F., Tagliaferri S., Lazzaretti M., Bonomini S., Crugnola M., et al. The proteasome inhibitor bortezomib affects osteoblastogenesis and bone formation in vitro and in vivo in multiple myeloma patients. Blood 108 (2006) 508
82. Terpos E., Heath D.J., Rahemtulla A., Zervas K., Chantry A., Anagnostopoulos A., et al. Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 135 (2006) 688-692
83. Body J.J., Greipp P., Coleman R.E., Facon T., Geurs F., Fermand J.P., et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 97 (2003) 887-892
84. Body J.J., Facon T., Coleman R.E., Lipton A., Geurs F., Fan M., et al. A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer. Clin Cancer Res 12 (2006) 1221-1228